GeneDx Holdings Corp. (WGS): Cost of Revenue

Annual figures by period end, from SEC filings.

$129.37M
Year ended 2025-12-31
$139.18M
Trailing 12 months to 2026-06-30
-20.9%
3-year compound annual growth
-5.9%
5-year compound annual growth
$261.44M2019-12-31: $113.39M2020-12-31: $175.30M2021-12-31: $228.80M2022-12-31: $261.44M2023-12-31: $112.56M2024-12-31: $111.05M2025-12-31: $129.37M$129.37M
2019-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$129.37M+16.5%2026-02-23, From 2025-01-01
2024-12-31$111.05M-1.3%2026-02-23, From 2024-01-01
2023-12-31$112.56M-56.9%2026-02-23, From 2023-01-01
2022-12-31$261.44M+14.3%2024-02-23, From 2022-01-01
2021-12-31$228.80M+30.5%2023-03-16, From 2021-01-01
2020-12-31$175.30M+54.6%2023-03-16, From 2020-01-01
2019-12-31$113.39Mn/a2022-03-14, From 2019-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Services-Health Services), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
GeneDx Holdings Corp. (WGS)2025-12-31$129.37M+16.5%
Omada Health, Inc. (OMDA)2025-12-31$89.27M+33.4%
Strata Critical Medical, Inc. (SRTA)2025-12-31$156.01M+33.1%
Vsee Health, Inc. (VSEE)2025-12-31$7.26M+123.9%
EUDA Health Holdings Ltd (EUDA)2025-12-31$3.83M+17.8%
Longduoduo Co Ltd (LDDD)2025-06-30$91.1K-47.4%
Agape ATP Corp (ATPC)2025-12-31$686.0K+21.7%

Compare WGS, OMDA, SRTA, VSEE side by side · Screen every company in Services-Health Services ↗